Pleiotropic effects of ARB in vascular metabolism - focusing on atherosclerosis- based cardiovascular disease

Current Vascular Pharmacology

Volumn 9, Issue 2, 2011, Pages 145-152

  Honjo, Tomoyuki ^a   Yamaoka Tojo, Minako ^b   Inoue, Nobutaka ^c  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c KOBE ROSAI HOSPITAL   (Japan)

Author keywords

LOX 1; NADPH oxidase; Oxidative stress; Vascular remodeling

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN P22; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA ANEURYSM; AORTA WALL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; BRAIN HEMORRHAGE; CELL VIABILITY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; HEART DEATH; HEART PROTECTION; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; ISCHEMIC HEART DISEASE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THORACIC AORTA ANEURYSM; VASCULARIZATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTIC ANEURYSM; ATHEROSCLEROSIS; BLOOD VESSELS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; NADPH OXIDASE; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; VASCULITIS;

EID: 79951687369     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111794519273     Document Type: Article

References (24)

1. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8.
2. Bánfi B, Clark RA, Steger K, Krause KH. Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J Biol Chem 2003; 278: 3510-3.
3. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004; 4: 181-9.
4. Honjo T, Otsui K, Shiraki R, et al. Essential role of NOXA1 in generation of reactive oxygen species induced by oxidized lowdensity lipoprotein in human vascular endothelial cells. Endothelium 2008; 15: 137-41.
5. Barry-Lane PA, Patterson C, van der Merwe M, et al. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest 2001; 108: 1513-22.
6. Azumi H, Inoue N, Takeshita S, et al. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 1999; 100: 1494-8.
7. Azumi H, Inoue N, Ohashi Y, et al. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 2002; 22: 1838-44.
8. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-8.
9. Takeshita S, Inoue N, Gao D, et al. Lysophosphatidylcholine enhances superoxide anions production via endothelial NADH/NADPH oxidase. J Atheroscler Thromb 2000; 7: 238-46.
10. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-5.
11. Terashima M, Ohashi Y, Azumi H, et al. Impact of NAD(P)H oxidase-derived reactive oxygen species on coronary arterial eemodeling: a comparative intravascular ultrasound and histochemical analysis of atherosclerotic lesions. Circ Cardiovasc Intervent 2009; 2: 196-204.
12. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and anti-oxidant prop- erties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008; 198: 22-8.
13. Jung KH, Chu K, Lee ST, et al. Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther 2007; 322: 1051-8.
14. Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001; 37: 440-4.
15. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with dietinduced hypercholesterolemia. Circulation 2000; 101: 1586-93.
16. Hayek T, Attias J, Coleman R, et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 1999; 44: 579-87.
17. Johnstone MT, Perez AS, Nasser I, et al. Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model. Circulation 2004; 110: 2060-5.
18. Takai S, Kim S, Sakonjo H, Miyazaki M. Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet. J Hypertens 2003; 21: 259-60.
19. Candido R, Allen TJ, Lassila M, et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 2004; 109: 1536-42.
20. Takaya T, Kawashima S, Shinohara M, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein Edeficient mice. Atherosclerosis 2006; 186: 402-10.
21. Waseda K, Ozaki Y, Takashima H, et al. Impact of angiotensin II receptor blockers on the progression and regression of coronary atherosclerosis: an intravascular ultrasound study. Circ J 2006; 70: 1111-5.
22. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312: 117-21.
23. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008; 358: 2787-95.
24. Ejiri J, Inoue N, Tsukube T, et al. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res 2003; 59: 988-96.